Drug to Treat Basal Cell Skin Cancer Approved after Priority Review
by on Wednesday, February 8th, 2012 | No Comments
Last week, the Food and Drug Administration (FDA) approved vismodegib (Erivedge) to treat adults with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and in patients whose cancer has metastasized.
View original post here: Drug to Treat Basal Cell Skin Cancer Approved after Priority Review